Articles tagged with Cancer Medication
A new analysis of raloxifene, a medication approved for osteoporosis prevention and treatment, found it reduces the risk of invasive, estrogen-receptor positive breast cancer in postmenopausal women by at least 50% for up to 8 years. The drug is also effective in reducing the risk of spine fractures.
The medical profession and national governments must develop strategies to meet the challenge of caring for survivors of teenage and young adult cancers. Cancer patients face a double whammy: the burden of the disease and the burden of treatment, leading to increased risk of second cancers, infertility, and long-term health issues.
A randomized controlled trial found that raloxifene reduced the risk of invasive ER-positive breast cancer by 44% in postmenopausal women. The drug did not affect non-invasive cancers or those with osteoporosis without high breast cancer risk.
Dan Savage, 25, survived testicular cancer at 20, gaining more confidence and starting his own art studio. He worries about losing regular medical checks after five years in remission, feeling the need for continued health monitoring.
Researchers from the University of São Paulo found tamoxifen to be an effective treatment against Leishmania amazonensis, one of the species causing cutaneous leishmaniasis in South America. In a rodent model, infected mice treated with tamoxifen showed significant parasite burden reduction and delayed skin ulcer development.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have created a new probe that allows for the modeling and measurement of the immune system in action. The probe enables scientists to monitor the immune response at the whole body level in 3D, facilitating faster diagnosis and treatment evaluation of immunological disorders.
A young patient was diagnosed with Hodgkin lymphoma after a 10-month delay due to referral pathway and hospital system errors. The delay resulted from incorrect referrals to non-cancer specialists, leading to prolonged delays in diagnosis and treatment.
A Duke University chemist has created a method to produce synthetic ketone molecules in only one shape, using a faster and more efficient process than previous methods. This breakthrough could lead to the development of drugs with fewer side effects and increased patient safety.
Researchers at OHSU Cancer Institute found that Ipilimumab effectively stimulates the immune system to fight prostate cancer, particularly in patients with resistant tumors. The drug works by blocking CTLA-4, releasing the safety brake and allowing the immune response to have a stronger anti-tumor effect.
Researchers found that metformin significantly increased pathologic complete response rates in diabetic women with early-stage breast cancer who took the drug during chemotherapy. The study showed a 24% response rate, three times higher than non-diabetic patients. Further investigation is needed to understand the mechanism of the drug.
Physician-scientists from NewYork-Presbyterian/Weill Cornell presented Phase II trial data showing a monoclonal antibody targeting prostate cancer cells effectively reduces PSA levels in patients with late-stage metastatic disease. The researchers also present results on RAD001, which slows cancer progression in recurrent endometrial c...
Researchers at OHSU Cancer Institute found that Sagopilone, a novel chemo drug, significantly reduced PSA levels and showed positive results in some cases of advanced prostate cancer. The study involved men with androgen-independent prostate cancer that has metastasized.
Karen H. Antman, MD, will receive the Distinguished Service Award for Scientific Leadership from ASCO at their annual meeting in Chicago. She is recognized for her development of a standard treatment regimen for sarcoma and has made significant contributions to cancer research.
Researchers found DNA abnormalities in the KIT gene linked to highly malignant skin cancers, offering hope for effective treatments. The study could lead to targeted therapies within 18 months.
A randomized phase II study found a trend towards increased survival in patients with advanced pancreatic cancer treated with axitinib plus gemcitabine compared to gemcitabine alone. The median overall survival was longer in the axitinib group, but the finding requires further investigation in a phase III trial.
Researchers at UT Southwestern Medical Center have developed a technique called bioluminescence imaging (BLI) to track the effectiveness of anti-cancer drugs. The technique involves adding luciferin to the bloodstream, which is carried to cells that have been altered to carry the firefly gene, causing them to emit light.
USC researchers have identified specific genetic markers in cancer cells that predict the benefit of a novel cancer drug. The study suggests that patients with tumors exhibiting these gene expression profiles may experience increased patient benefit from the incorporation of the drug into their treatment.
Women who have taken menopausal hormone therapy before are at a 37% higher risk of breast cancer than those who never used it. The risk is highest when taking combined estrogen and progestin therapies, with an increased risk by 73% during use.
Researchers at the University of Pennsylvania School of Medicine have identified a fruit fly protein called Argos that acts as a decoy receptor to neutralize tumor growth factors. This discovery may lead to new cancer drug designs by mimicking the silent binding of growth factors, similar to existing treatments like Avastin.
Long-term cancer survivors are experiencing unmet needs for symptom management, leading to a poor quality of life. The European CanCer Organisation is working to bridge the gap between oncology and palliative care to provide comprehensive care for all stages of disease.
A University of Rochester team has identified approximately 100 genes that cooperate to cause malignant cell transformation, providing a potential roadmap for next-generation cancer therapies. These genes, known as CRGs, encode proteins that regulate cell signaling and metabolism.
An experimental drug, OSU-HDAC42, has blocked prostate cancer progression in mice with an aggressive form of the disease. The agent reactivates genes that normally protect against cancer, shifting tumor progression to a more benign direction.
A US clinical trial confirms early use of targeted therapies like gefitinib can improve lung cancer patient outcomes. The study found that 31 out of 34 patients with sensitizing EGFR mutations showed significant tumor shrinkage or no growth after receiving Iressa treatment.
A study at Massachusetts General Hospital confirms the benefits of surgery for patients with persistent gastroesophageal reflux disease (GERD) symptoms. Most patients reported improved quality-of-life scores and high satisfaction rates with their long-term results, suggesting that antireflux surgery is an excellent treatment alternative.
A new study published in the Annals of Internal Medicine has found that sequential therapy is superior to standard treatment for eradicating H. pylori, with potential implications for future treatments. Additionally, the study reveals a higher risk of certain cancers among HIV-infected patients and suggests a possible association betwe...
Researchers at the University of Chicago Medical Center report positive results from a human trial of sorafenib, a cancer drug, as a treatment for pulmonary hypertension. Eight out of nine patients improved their exercise capacity and six experienced significant improvements in right ventricular ejection fraction.
Researchers found that NSAIDs can reduce adenoma burden by 64% and prevent advanced adenomatous polyp detection by 35%. Additionally, celecoxib has shown promise in preventing post-ERCP pancreatitis.
A Phase II clinical trial led by researchers at The University of Texas M. D. Anderson Cancer Center found that Iressa enhanced the effectiveness of hormonal therapy in treating specific types of metastatic breast cancer. The combination resulted in a 45% reduction in risk and improved clinical benefits for patients.
Researchers at WashU Medicine found that a bone-strengthening drug called zoledronic acid reduced the growth of breast tumor cells in bones by 23% after three months. Women treated with the drug were also less likely to develop large metastatic tumors, suggesting it may help prevent cancer spread.
A first-of-its-kind lung cancer chemoprevention trial found Celebrex reduces precancerous lesion proliferation and is safe for high-risk individuals. The study demonstrated the importance of COX-2 inhibition in preventing lung cancer, with potential implications for cancer prevention and treatment.
Childhood cancer survivors who received cyclophosphamide chemotherapy are at a higher risk of developing bladder cancer. Researchers found that the risk increases over time, with a significant increase after 20 years post-treatment.
A new study shows that an anesthetic injection into nerves in the neck can significantly reduce the frequency and severity of hot flashes and night awakenings in breast cancer survivors. The treatment, called a stellate ganglion block, was shown to provide lasting relief for most patients.
A pilot study found that stellate-ganglion block reduced hot flushes in breast cancer survivors by up to 90% and improved sleep quality. The procedure provided long-term relief with minimal side effects, increasing overall quality of life and compliance with treatment.
Researchers at University of Oklahoma discovered a chemical compound that prevents cancer in lab tests, successfully stopping normal cells from turning into cancer cells and inhibiting tumor growth. The compound, SHetA2, is being developed by NCI as a cancer prevention drug to be taken daily like a multi-vitamin.
A clinical trial evaluating sorafenib added to carboplatin/paclitaxel chemotherapy for lung cancer patients showed the combination offers no improved overall survival. Sorafenib results in worse outcomes for some patients with squamous histology.
Researchers have developed a test to accurately distinguish between squamous and non-squamous forms of non-small-cell lung cancer based on microRNA levels. This method can improve diagnosis and treatment guide for patients with the disease.
A study published in JAMA found that cisplatin is not an effective alternative to standard treatment for anal cancer, with a lower disease-free survival rate and more colostomies. The research suggests that fluorouracil plus mitomycin and radiotherapy remains the best treatment option for patients with anal canal cancer.
A randomized controlled trial found that chemotherapy with cisplatin before concurrent chemoradiation did not improve disease-free survival for patients with anal canal cancer. The therapy resulted in a higher rate of colostomy procedures and was associated with severe hematologic toxicity.
Researchers detail chemotherapy's damage to the brain, finding that healthy cells die off long after treatment ends. The study identifies 5-fluorouracil as a contributor to chemo brain, with damaged oligodendrocytes leading to cognitive decline and demyelination.
A new chemotherapy combination of docetaxel and capecitabine showed no improved efficacy in early breast cancer treatment, but increased non-haematological toxicities. The study found that the addition of capecitabine produced more side effects, such as hand-foot syndrome and diarrhoea.
A phase 1 clinical trial showed AME-133v had a potent tumor-halting response in patients with follicular lymphoma. The drug triggered signaling pathways within cells to slow or stop cancer growth, while causing minimal side effects.
OHSU Cancer Institute researchers discovered the gene ASPP2 is necessary in eliminating cancer cells. This protein activates pathways that tell cancer cells to die, protecting them from one of the steps leading to cancer. The study may lead to better therapies and cancer care for patients.
A new clinical trial has shown promising results with riluzole, a U.S. FDA-approved drug, slowing the growth of late-stage melanoma in human patients. The Phase 0 trial found three solid positive responses in nine patients, indicating potential as an adjunct to surgical treatment for stage 3 or 4 melanoma.
Researchers at UAB have discovered that triphendiol induces cell death in pancreatic and bile duct cancer cells, slowing tumor growth and sensitizing tumors to chemotherapy treatments. The investigational drug has shown promise as a potential treatment for pancreatic adenocarcinoma.
A new global alliance for pharmacogenomics is launching, aiming to identify genetic factors contributing to individual responses to medicines. Initial projects will focus on understanding breast cancer treatment effectiveness, pancreatic cancer side effects, and drug-induced heart rhythm disorders.
Researchers at Rutgers University have discovered that combining Celebrex and Lipitor can stop the transition of early prostate cancer to its more aggressive stage. This breakthrough could lead to a new treatment strategy for men with early-stage disease, potentially preventing cancer progression and saving lives.
Researchers at Thomas Jefferson University have found that common blood pressure medications can inhibit pancreatic cancer cell growth and cause cell death. The study suggests that these drugs may be part of a novel strategy to control the growth and spread of cancer.
Scientists at Georgetown University Medical Center have identified a small molecule that can block the action of the EWS-FLI1 fusion protein responsible for Ewing's sarcoma. This breakthrough could lead to the development of a targeted therapy for this rare and aggressive cancer.
Researchers found that a tumor protein present in aggressive breast cancers correlates with poor prognosis and growth/spread of disease. GRB-7 protein is related to HER-2/Neu gene, influencing treatment response and potentially informing clinical predictions and new therapies.
The Landon Foundation-AACR INNOVATOR Award for Cancer Prevention Research supports early career scientists, while the International Collaboration award promotes global cooperation to accelerate progress against cancer. The awards aim to encourage innovative approaches to cancer prevention and treatment.
Researchers have found that two drugs can bind to receptor sites on some tumors in different places at the same time. This discovery implies the possibility of a new combination therapy targeting EGFR proteins, which are present on the surface of many types of cancer cells.
Scientists at Northwestern University successfully blocked the communication between inflammatory cells and prostate cancer cells, reducing their invasive activity. The findings suggest using existing anti-inflammatory drugs to control cancer spread and metastasis.
A new drug candidate, TG101348, has been developed to treat a rare class of blood diseases called myeloproliferative disorders (MPD). The drug, which targets the JAK2 protein that causes overproduction of red blood cells, shows promise in halting disease progression and reversing excessive production of red blood cells.
A simple and fast screening technique has been developed to identify promising synthetic molecules that mimic therapeutic antibodies and can treat cancer at a lower cost. The new method screened over 300,000 peptoids and isolated five candidates that showed promise in treating human tumors.
Researchers at Boston University School of Medicine have developed a clinicogenomic model to test for lung cancer with increased sensitivity and specificity. The model combines gene expression and clinical risk factors, offering improved accuracy in identifying patients who would benefit from further invasive testing.
Researchers at UC Irvine have discovered the key to controlling polyketide ring formation, enabling the creation of new drugs for cancer treatment and cholesterol reduction. This breakthrough could lead to significant advancements in pharmaceuticals, with potential applications in obesity treatment and stem cell research.
A new breed of targeted cancer drugs is attacking specific proteins in cancer cells, but also causes devastating dermatologic side effects. The Cancer Skin Care Program at Northwestern University provides specially formulated lotions and drugs to help patients preserve their dignity and quality of life.
Researchers found that NSAIDs up-regulate anti-metastatic genes such as SPARC and TIMP-2 in human lung cancer cells. The study reveals a novel mechanism by which NSAIDs inhibit tumor invasion and metastasis, potentially providing a new strategy for cancer treatment.
A new mathematical model could revolutionize how scientists study cellular signaling pathways, potentially leading to more effective treatments for cancer and other diseases. The model takes advantage of today's computing power to provide a superior tool for understanding the complex interactions between cell signals.
OHSU Cancer Institute researchers found that SGX393 is effective against Gleevec-resistant chronic myeloid leukemia (CML) by inhibiting T315I mutant and most, but not all, other Gleevec-resistant mutants. The combination of SGX393 with Sprycel or Tasigna completely suppressed resistance in a pre-clinical study.